Aguettant Diagnostics, incorporated on 1st July 2022, is the diagnostic entity of Aguettant Group. Based in Lyon, on the same site as its parent company, Aguettant Diagnostics offers 2000m² of infrastructures dedicated to the development, the industrialization and the production of Elisa tests and rapid lateral flow tests. This diagnostic entity has been created in continuity with the development of the medtech Promise Proteomics which propose innovative solutions for the quantification of biotherapies and subsidiary of Aguettant Group.